The Cartherics allogeneic (off-the-shelf) technology is based on umbilical cord blood cells from rare histocompatible donors that are converted to stem cells (iPSCs) and gene edited to introduce CARs and to knock-out genes that inhibit immune function. These are then converted into CAR-T or CAR-NK cells to enhance the patients’ own immune system to combat any cancer) cell growth. These cells immediately attack the cancer and some can remain long-term to prevent relapse. They retain the CAR and deletion of the immune inhibitory gene(s)and hence provide cover more broadly than do antibodies and other cancer drugs.